Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma

NCT06764355 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

ESCC
Total Neoadjuvant Treatment
Pathological Complete Response

Interventions

DRUG: Tislelizumab
DRUG: Paclitaxel
DRUG: Cisplatin
RADIATION: Chemoradiotherapy

Sponsor

National Taiwan University Hospital

Collaborators

[object Object]